McKesson Corporation 10-Q Summary: Q1 Fiscal 2027 (Ended June 30, 2026)
Business Context and Reporting Period
This report covers the first quarter of McKesson Corporation's fiscal year 2027, ended June 30, 2026. The Company is a diversified healthcare services leader operating through four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The reporting period reflects a new segment structure implemented in Q2 fiscal 2026 and includes significant strategic transactions, including the sale of a minority interest in Medical-Surgical Solutions and the divestiture of Norwegian operations.
Key Financial Metrics
| Metric | Q1 2027 (Current) | Q1 2026 (Prior Year) |
|---|---|---|
| Revenues | $105,380 million | $97,827 million |
| Gross Profit | $3,685 million | $3,279 million |
| Gross Margin | 3.50% | 3.35% |
| Operating Income | $1,319 million | $1,036 million |
| Net Income (Total) | $1,032 million | $831 million |
| Net Income Attributable to McKesson | $614 million | $784 million |
| Diluted EPS (Attributable to McKesson) | $5.15 | $6.25 |
| Cash and Cash Equivalents | $5,164 million | $2,418 million (End of Period) |
| Total Debt | $9,729 million | $6,526 million (Prior Quarter) |
| Working Capital | ($7,519 million) | ($9,807 million) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% year-over-year, driven by market growth in the North American Pharmaceutical segment and a 33% surge in the Oncology & Multispecialty segment due to higher specialty pharmaceutical sales.
- Earnings Decline: Despite higher total net income, net income attributable to McKesson Corporation decreased 22% to $614 million. This was primarily due to a significant increase in "Net income attributable to noncontrolling interests" ($418 million vs. $47 million prior year), driven by the valuation adjustment of redeemable noncontrolling interests in Medical-Surgical Solutions and Core Ventures.
- Restructuring Charges: Restructuring, impairment, and related charges increased to $136 million from $47 million, largely due to initiatives in the Prescription Technology Solutions segment and Corporate functions.
- Debt Expansion: Total debt increased significantly to $9.7 billion from $6.5 billion at the end of the prior quarter, primarily due to new term loans ($3.2 billion) secured by the Medical-Surgical Solutions subsidiary to fund its separation strategy.
- Share Repurchases: The Company returned $2.6 billion to shareholders, including $2.5 billion in share repurchases and $102 million in dividends.
Guidance, Outlook, and Risks
- Capital Allocation: The Board approved an additional $5.0 billion share repurchase authorization in April 2026. The quarterly dividend was raised from $0.82 to $0.94 per share in July 2026.
- Medical-Surgical Solutions Separation: The Company is proceeding with the separation of this segment. Apollo Global Management acquired a 13% minority interest for approximately $1.25 billion in convertible preferred equity. McKesson retains operating control and majority ownership.
- Restructuring Outlook: Management anticipates total charges of $230 million to $310 million for new Corporate initiatives and $200 million to $250 million for Prescription Technology Solutions initiatives, with completion expected by fiscal 2028 and 2029, respectively.
- Litigation Risks: The Company maintains a total estimated litigation liability of $5.7 billion related to opioid claims. While a $34 million credit was recorded this quarter due to a favorable outcome in the City of Baltimore case, the Company faces ongoing uncertainty regarding non-governmental plaintiff claims and Canadian litigation.
- Regulatory Environment: The Company highlights risks associated with government policies, healthcare funding changes, and regulatory uncertainty affecting the industry.
Investor Verification Checklist
- Noncontrolling Interest Impact: Verify the sustainability of the $418 million noncontrolling interest charge and its specific impact on future diluted EPS calculations.
- Medical-Surgical Debt Structure: Review the terms of the $3.2 billion term loans secured by the Medical-Surgical subsidiary and the implications for the parent company's balance sheet.
- Opioid Liability Accruals: Monitor the $5.7 billion litigation liability for potential adjustments based on ongoing trials and settlement negotiations.
- Restructuring Execution: Track the progress of the $650 million to $700 million enterprise-wide restructuring initiatives approved in fiscal 2025.
- Share Count Reduction: Confirm the final share count impact of the Accelerated Share Repurchase (ASR) programs initiated in March and May 2026.